Morgan Stanley sees FDA approval of GILD's Lenacapavir
Morgan Stanley expects the FDA to approve Gilead Sciences (NASDAQ:GILD)' Lenacapavir (LEN) for HIV prevention (PrEP) on or before its June 19 PDUFA date, a move that the bank believes could drive ...
Trump's Funding Cuts Halt Rollout Of HIV Prevention Drug
Lenacapavir, an innovative twice-yearly injection that prevents HIV transmission, was recognized as the breakthrough medicine ...
Gilead’s lenacapavir applications for HIV gain EMA validation
The latest announcement follows the recent US Food and Drug Administration (FDA) acceptance of the company’s new drug ...
Pharmabiz6h
EMA validates Gilead’s MAA and EU-Medicines for all application for twice-yearly lenacapavir for HIV prevention
Foster City, California Tuesday, February 25, 2025, 16:00 Hrs [IST] ...
BlackDoctor21h
Health Equity is Profitable—So Why Isn’t It a Priority?
The discussion ended with a bold call to action for businesses, healthcare providers, and policymakers: health equity must be a priority—not just ethically, but economically. As Burgess put it: “This ...